Go to the list of all blogs
Niko Sharks's Avatar
published in Blogs
Jun 11, 2023
Diana Shipping (DSX) Set to Pay Dividends on July 10, 2023: An Analysis

Diana Shipping (DSX) Set to Pay Dividends on July 10, 2023: An Analysis

In a recent announcement, Diana Shipping Inc. (DSX) has confirmed that it will distribute dividends to its shareholders on July 10, 2023. The dry bulk shipping company's Board of Directors has declared a dividend of $0.15 per share. This follows the previous payout of the same amount on March 20, 2023, marking a consistent return to investors for consecutive quarters.

The record date, which is the date by which an investor needs to be on the company’s books as a shareholder to receive the dividend, has been set for July 10, 2023. It's essential for potential investors and current shareholders to understand that if they buy the stock on or after the ex-dividend date of June 09, 2023, they will not receive the upcoming dividend. Instead, the seller would reap the dividends. This point in time is when the company starts trading "ex-dividend," and it typically falls a few business days before the record date.

From a financial standpoint, the decision to maintain the dividend level demonstrates that Diana Shipping continues to generate sufficient earnings, allowing the company to maintain this shareholder-friendly policy. However, to gain a comprehensive understanding, we need to scrutinize the company's financial statements and earnings reports.

While the specific earnings details were not provided in the brief, a few general points can be inferred from the steady dividend payments. First, consistent dividends usually indicate a company's robust financial health and a relatively stable cash flow. Diana Shipping’s capacity to maintain its dividend rate for these two successive quarters indicates that the company is likely maintaining profitability and cash reserves, which is a promising sign for investors.

Second, regular dividends provide a stable income stream for shareholders, which can be particularly appealing in volatile market conditions. Investors in Diana Shipping, thus, have the benefit of both potential capital gains from stock appreciation and the stable return from dividends.

Lastly, dividend payouts are a testament to a company's confidence in its future earning potential. By declaring and sticking to a dividend, Diana Shipping is expressing its management's belief in the company's sustainable earnings.

However, investors should remember that while dividends are an important part of total return, they are not the only factor to consider when investing in a company. A thorough review of the company’s financial health, business model, industry positioning, and potential for future earnings growth should always accompany dividend analysis.

The forthcoming dividend payment from Diana Shipping Inc. on July 10, 2023, signals a positive outlook, steady cash flow, and a commitment to returning capital to shareholders. However, investors must keep the ex-dividend date in mind to ensure they are eligible to receive dividends.

Related Ticker: DSX

DSX's Stochastic Oscillator slumps oversold zone

The Stochastic Oscillator for DSX moved into oversold territory on September 23, 2026. Be on the watch for the price uptrend or consolidation in the future. At that time, consider buying the stock or exploring call options.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

Following a +4.01% 3-day Advance, the price is estimated to grow further. Considering data from situations where DSX advanced for three days, in 157 of 243 cases, the price rose further within the following month. The odds of a continued upward trend are 65%.

The Aroon Indicator entered an Uptrend today. In 124 of 212 cases where DSX Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 58%.

Bearish Trend Analysis

The 10-day RSI Indicator for DSX moved out of overbought territory on September 21, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 28 similar instances where the indicator moved out of overbought territory. In 23 of the 28 cases, the stock moved lower in the following days. This puts the odds of a move lower at 82%.

The Momentum Indicator moved below the 0 level on September 21, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on DSX as a result. In 72 of 96 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 75%.

The Moving Average Convergence Divergence Histogram (MACD) for DSX turned negative on September 21, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 52 similar instances when the indicator turned negative. In 37 of the 52 cases the stock turned lower in the days that followed. This puts the odds of success at 71%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where DSX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 67%.

DSX broke above its upper Bollinger Band on September 02, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Fundamental Analysis (Ratings)

The Tickeron Price Growth Rating for this company is 37 (best 1 - 100 worst), indicating steady price growth. DSX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is 69 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Valuation Rating of 76 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.659) is normal, around the industry mean (1.467). P/E Ratio (5.959) is within average values for comparable stocks, (13.954). DSX's Projected Growth (PEG Ratio) (9.070) is very high in comparison to the industry average of (0.581). Dividend Yield (0.014) settles around the average of (0.047) among similar stocks. P/S Ratio (1.554) is also within normal values, averaging (1.795).

The Tickeron PE Growth Rating for this company is 96 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is 96 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. DSX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 63, placing this stock worse than average.

Industry description

The marine shipping industry provides passenger transportation or cargo shipping services via waterways. This industry includes freight towage, ferry services and warehousing on deep-sea and inland waterways. The aviation sector may have reduced the popularity of sea travel for several passengers, but it is still in demand for short trips and pleasure cruises. Teekay Offshore Partners L.P. Cum Red Perp Pfd., Kirby Corporation and Seaspan Corporation are some of the well-known names in the business.

Market Cap

The average market capitalization across the Marine Shipping Industry is 1.33B. The market cap for tickers in the group ranges from 2K to 49.38B. AMKBY holds the highest valuation in this group at 49.38B. The lowest valued company is PRGNF at 2K.

High and low price notable news

The average weekly price growth across all stocks in the Marine Shipping Industry was -3%. For the same Industry, the average monthly price growth was 4%, and the average quarterly price growth was 29%. VNTG experienced the highest price growth at 22%, while NCT experienced the biggest fall at -38%.

Volume

The average weekly volume growth across all stocks in the Marine Shipping Industry was -17%. For the same stocks of the Industry, the average monthly volume growth was 20% and the average quarterly volume growth was 27%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 33
P/E Growth Rating: 48
Price Growth Rating: 49
SMR Rating: 67
Profit Risk Rating: 62
Seasonality Score: -31 (-100 ... +100)
View a ticker or compare two or three
DSX
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

a holding company, which provides shipping transportation services

Industry MarineShipping

Industry
Marine Shipping
Address
175 64 Palaio Faliro
Phone
+30 2109470100
Employees
939
Web
https://www.dianashippinginc.com
Interact to see
Advertisement
INSM shares are surging approximately +10% in premarket trading on Monday, March 23, 2026, from a prior close of $136.00, placing the premarket price near $149.60. The primary catalyst is the release of positive topline results from the Phase 3 ENCORE trial of ARIKAYCE® in patients with newly diagnosed or recurrent MAC (Mycobacterium avium complex) lung disease — a readout Insmed had flagged as expected in "March or April 2026".
CF shares are trading approximately -6% lower in Monday's premarket session, dropping from a Friday close of $124.90 to approximately $117.41. Primary catalyst: President Trump announced a five-day pause on strikes against Iranian energy infrastructure following "very good" diplomatic signals, triggering a sharp unwind of the geopolitical risk premium embedded in fertilizer stocks.
APGE shares surged approximately 16% in premarket trading on March 23, 2026, after the company announced positive 52-week data from Part A of its Phase 2 APEX clinical trial. The primary catalyst is a highly anticipated clinical readout showing that zumilokibart (APG777) delivered durable and deepening responses in patients with moderate-to-severe atopic dermatitis at both every 3-month and 6-month dosing intervals.
Shares of VALN are plummeting approximately 35% in Monday's session, from a Friday close of $10.66 to roughly $6.93, in heavy volume trading. The primary catalyst is the release of Phase 3 VALOR trial topline results for Valneva's Lyme disease vaccine candidate, co-developed with PFE (Pfizer) — results that showed strong clinical efficacy but failed to meet the pre-determined statistical criterion for the primary endpoint.
AXTI is surging approximately +11.00% in Monday's session, trading near $60.21, up from a prior closing price of $54.24. The move extends the stock's post-earnings rally that began last Thursday when shares jumped more than 19% following AXT's Q4 2025 results.
Tower Semiconductor (TSEM) shares are surging approximately +10% intraday on Monday, March 23, trading around $180, up from the previous close of $163.63 on March 20, 2026. The primary catalyst is the opening day of APEC 2026 in San Antonio, Texas, where Tower Semiconductor is presenting its newly unveiled Gen3 BCD power management platform designed to address escalating AI data center power demands.
CD is indicated down about 17% in premarket trading after the latest completed session, pointing to a sharp negative market reaction heading into the open. The stock’s weakness comes against a backdrop of lingering uncertainty following its privatization and delisting process from Nasdaq, which has left limited liquidity and a thinner news flow around the name.
SEDG is indicated down roughly 9% in premarket trading, following a strong advance in the prior regular session. The pullback comes after shares rallied on optimism around new product launches and an analyst upgrade, leaving the stock vulnerable to profit-taking and volatility.
NTGR shares surged approximately 11% in premarket trading on March 24, 2026, building on a roughly 20% overnight jump in the prior session. The primary catalyst is a landmark Federal Communications Commission (FCC) ruling that prohibits all imports of consumer routers manufactured overseas, citing national security concerns.
ANNA is surging approximately +20.00% in Tuesday's premarket session, rebounding sharply from Monday's -22.84% decline. The primary catalyst remains the ongoing U.S.-Iran military conflict, which disrupted Qatari LNG exports and drove European benchmark natural gas prices to multi-year highs.
Concentrix Corporation (CNXC) shares are falling approximately 11% in Tuesday's premarket session after the company released its fiscal Q1 2026 earnings report before market open. Adjusted diluted EPS came in at $2.61, missing the Wall Street consensus estimate of approximately $2.64.
Shares of Karyopharm Therapeutics (KPTI) are trading approximately 12% lower in Tuesday's premarket session, with the previous close at $7.63. The primary catalyst is the March 24 release of topline Phase 3 SENTRY trial data, in which the company met only one of two co-primary endpoints.
IBRX shares are down approximately 23% in Tuesday's session, trading near $7.24 after closing at $9.40 on Monday, March 23. The sharp decline follows an 11%+ surge in the prior session, with profit-taking and valuation pressure cited as primary triggers.
Shares of Circle Internet Group (CRCL) are down approximately 9% in Tuesday morning trading, extending a pullback from recent multi-month highs above $126. The primary catalyst appears to be a broad crypto-sector risk-off wave, with Bitcoin sliding below $69,000 and the Fear & Greed Index dropping to extreme fear territory.
ALM shares are indicated down about 11% in early Tuesday trading after closing the prior session at $16.93. The move comes after a powerful multi‑month rally that took the stock from below $3 to an intraday high of $22.55 earlier in March, leaving it vulnerable to profit-taking and volatility.​
LUNR shares are indicated down about 7% in Tuesday premarket trading after closing the last regular session at $20.31. The pullback follows a powerful rally driven by strong 2026 revenue guidance of $900 million–$1 billion and upbeat analyst commentary, including price target hikes and buy ratings.
MAZE shares are trading approximately 27% lower in premarket on March 25, 2026, after the company reported its highly anticipated Phase 2 HORIZON trial topline data for lead drug candidate MZE829. The catalyst is a dual announcement: Phase 2 clinical data for MZE829 in APOL1-mediated kidney disease (AMKD) alongside Q4 and full-year 2025 financial results.
ARM shares surged approximately +10% in premarket trading on March 25, 2026, hitting $148.6 from a prior close of approximately $135. The primary catalyst is Arm's historic strategic pivot: the company announced it will begin selling its own self-developed AGI CPU chips, breaking its decades-long "IP licensing only" business model.
Shares of Enliven Therapeutics (ELVN) are surging approximately +15% in premarket trading on March 25, 2026, driven by renewed investor enthusiasm around the company's advancing clinical program for ELVN-001 in chronic myeloid leukemia (CML). The stock's prior closing price on March 24, 2026 was $31.15, placing the premarket indicated price near $35.82.
AVXL shares are down approximately 29% in premarket trading on Wednesday, March 25, 2026, falling to roughly $2.97 from the prior close of $4.19. The primary catalyst is Anavex's formal withdrawal of its marketing authorization application (MAA) for blarcamesine from the European Union, announced in the early hours of March 25, 2026.